Laboratorios Farmaceuticos Rovi has a current ratio of 3.66. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Laboratorios Farmaceuticos Rovi's Current Ratio or its related term are showing as below:
XMAD:ROVI'
s Current Ratio Range Over the Past 10 Years
Min: 1.77 Med: 2.63 Max: 3.7
Current: 3.66
During the past 13 years, Laboratorios Farmaceuticos Rovi's highest Current Ratio was 3.70. The lowest was 1.77. And the median was 2.63.
XMAD:ROVI's Current Ratio is ranked better than 75.2% of 996
companies
in the Drug Manufacturers industry
Industry Median: 2
vs XMAD:ROVI: 3.66
Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Laboratorios Farmaceuticos Rovi Current Ratio Related Terms
Laboratorios Farmaceuticos Rovi Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Laboratorios Farmaceuticos Rovi Current Ratio Chart
XMAD:ROVI vs ZTS, UTHR, VTRS: Current Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Laboratorios Farmaceuticos Rovi's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Laboratorios Farmaceuticos Rovi Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Laboratorios Farmaceuticos Rovi's Current Ratio distribution charts can be found below:
* The bar in red indicates where Laboratorios Farmaceuticos Rovi's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Laboratorios Farmaceuticos Rovi (XMAD:ROVI) has a Current Ratio of 3.66 as of Mar. 2026. This is 39% above median its historical median of 2.63. Over the past decade, Laboratorios Farmaceuticos Rovi's Current Ratio has ranged from 1.77 to 3.70. According to the industry distribution chart, Laboratorios Farmaceuticos Rovi ranks #247 out of 996 companies in the Drug Manufacturers industry, placing it in the top 24.8%.
Is Laboratorios Farmaceuticos Rovi's Current Ratio too high?
Laboratorios Farmaceuticos Rovi's current Current Ratio of 3.66 is 39% above median its 10-year median of 2.63. Over the past 10 years, this metric has ranged from a low of 1.77 to a high of 3.70. The Drug Manufacturers industry median Current Ratio is 2.00. Laboratorios Farmaceuticos Rovi's value of 3.66 is 83% above this industry median. Based on the distribution chart, Laboratorios Farmaceuticos Rovi ranks #247 out of 996 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Laboratorios Farmaceuticos Rovi has a GF Score™ of 97/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Laboratorios Farmaceuticos Rovi's Current Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Laboratorios Farmaceuticos Rovi ranks #247 out of 996 companies for Current Ratio. This places Laboratorios Farmaceuticos Rovi in the top 25% of its industry — outperforming the majority of peers. The industry median Current Ratio is 2.00. Laboratorios Farmaceuticos Rovi's value of 3.66 is 83% above this benchmark. Historically, Laboratorios Farmaceuticos Rovi's own Current Ratio has ranged from 1.77 to 3.70 over the past decade. While the company's 10-year median is 2.63 vs. the industry median of 2.00, Laboratorios Farmaceuticos Rovi has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 996 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Laboratorios Farmaceuticos Rovi's current Current Ratio of 3.66 is 83% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Laboratorios Farmaceuticos Rovi's current Current Ratio is 3.66, which is 39% above median its own 10-year median of 2.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laboratorios Farmaceuticos Rovi stock overvalued right now?
Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi (XMAD:ROVI) is currently considered Modestly Overvalued. The stock's GF Value™ is €50.97, compared to a current price of €57.85 — trading 13.5% above its estimated fair value. The current Current Ratio is 3.66, which is 39% above median its 10-year median of 2.63 and 83% above the Drug Manufacturers industry median of 2.00. Laboratorios Farmaceuticos Rovi's overall GF Score™ is 97/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Laboratorios Farmaceuticos Rovi (XMAD:ROVI), the current Current Ratio is 3.66 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Overvalued in 2026?
Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi stock appears to be overvalued.
The current stock price of €57.85 is trading 13.5% above its estimated GF Value™ of €50.97.
GuruFocus considers Laboratorios Farmaceuticos Rovi to be Modestly Overvalued.
Key valuation signals for XMAD:ROVI:
Current Ratio: 3.66 (39% above median its 10-year median of 2.63)
GF Value™: €50.97 vs. price of €57.85 (13.5% above fair value)
Industry Position: 83% above the Drug Manufacturers median (#247 of 996)
No single metric tells the full story. See the XMAD:ROVI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Laboratorios Farmaceuticos Rovi Business Description
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.
97GF Score
Get the complete analysis for XMAD:ROVI
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:ROVI has been successfully added to your 
